About Newron Pharmaceuticals
Newron Pharmaceuticals is a company based in Milan (Italy) founded in 1999. Newron Pharmaceuticals has raised $54.94 million across 10 funding rounds from investors including Apax Partners, European Investment Bank and 3i Group. Newron Pharmaceuticals offers products and services including Xadago and Evenamide. Newron Pharmaceuticals operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Reunion Neuroscience, Cerecor and Neurovance, among others.
- Headquarter Milan, Italy
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Newron Pharmaceuticals S.P.A.
-
Annual Revenue
$54.03 M (USD)456.35as on Dec 31, 2024
-
Net Profit
$16.66 M (USD)0as on Dec 31, 2024
-
EBITDA
$27.73 M (USD)0as on Dec 31, 2024
-
Total Equity Funding
$54.94 M (USD)
in 10 rounds
-
Latest Funding Round
$45.94 M (USD), Debt – Conventional
Jun 28, 2019
-
Investors
Apax Partners
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Newron Pharmaceuticals
Newron Pharmaceuticals is a publicly listed company on the SIX with ticker symbol NWRN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Newron Pharmaceuticals
Newron Pharmaceuticals offers a comprehensive portfolio of products and services, including Xadago and Evenamide.
Treatment for Parkinson's disease in CNS disorders
Add-on therapy for schizophrenia patients
People of Newron Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Newron Pharmaceuticals
Newron Pharmaceuticals has successfully raised a total of $54.94M across 10 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $45.94 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Newron Pharmaceuticals
Newron Pharmaceuticals has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Apax Partners, European Investment Bank and 3i Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked | |
|
Private equity firm focused on company buyouts
|
Locked | Locked | Locked | |
|
Late-stage life sciences investments are managed via VC and PE.
|
Locked | Locked | Locked |
Investor details for Newron Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Newron Pharmaceuticals
Investment portfolio details for Newron Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Newron Pharmaceuticals
Detailed financials for Newron Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Newron Pharmaceuticals Comparisons
Peer comparison for Newron Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Newron Pharmaceuticals
Newron Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Reunion Neuroscience, Cerecor and Neurovance, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| Locked | Locked | Locked |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| Locked | Locked | Locked |
Therapeutics for mental health conditions are developed using serotonergic psychedelics.
|
|
| Locked | Locked | Locked |
Therapeutics for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
Detailed competitors of Newron Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Newron Pharmaceuticals
Complete news archive for Newron Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Newron Pharmaceuticals
Newron Pharmaceuticals was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Newron Pharmaceuticals is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
Anders Haegerstrand is the current CEO of Newron Pharmaceuticals.
Newron Pharmaceuticals is a funded company, having raised a total of $54.94M across 10 funding rounds to date.
Annual revenue of Newron Pharmaceuticals is $54.03M as on Dec 31, 2024.
Newron Pharmaceuticals was founded in 1999 and is headquartered in Milan, Italy. Operations focus on the pharmaceutical sector, with a pipeline of drug candidates targeted at central nervous system disorders and pain conditions. Key candidates include Xadago for Parkinsons disease treatment, Evenamide for schizophrenia symptoms, Sarizotan for Rett syndrome, and ralfinamide for rare pain indications. Development efforts are directed toward unmet medical needs in neurology.
Newron Pharmaceuticals's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Seaport Therapeutics.
Newron Pharmaceuticals offers Xadago and Evenamide.
Yes, Newron Pharmaceuticals is publicly traded on SIX under the ticker symbol NWRN.
Newron Pharmaceuticals has 8 investors. Key investors include Apax Partners, European Investment Bank, 3i Group, Atlas Venture, and HBM Healthcare Investments.
The ticker symbol of Newron Pharmaceuticals is NWRN on SIX.